S 4472
Passed a chamber
Extends the Accelerating Access to Critical Therapies for ALS Act through fiscal year 2031 and tightens the rules for federal grants that fund research on ALS treatments.
Official title: Accelerating Access to Critical Therapies for ALS Reauthorization Act of 2026
Timeline each lane is a chamber; dates pull from congress.gov actions
House
Received
10-AUG-2026
Senate
Introduced
30-APR-2026
Referred
30-APR-2026
Approved by committee
17-JUN-2026
Reported
16-JUL-2026
On the calendar
16-JUL-2026
Passed
04-AUG-2026
- Extends the program's authorization from fiscal years 2022 through 2026 to fiscal years 2027 through 2031.
- Requires grant applicants to describe how grant-funded data supports ALS research and to assure that they promptly report available safety data from ongoing clinical trials.
- Requires the Food and Drug Administration to publish rare neurodegenerative disease action plans within 1 year of enactment and every 5 years after, including progress on the prior plan.
- Requires the Department of Health and Human Services to report to Congress within 4 years on the program's effectiveness and corrects two misspellings in the existing law.
Covers an older version. The newest CRS summary describes the bill as of "Reported to Senate" (16-JUL-2026); the text has changed since (Engrossed in Senate, 04-AUG-2026).
CRS is the Library of Congress's nonpartisan research office. Read it on congress.govHealth
■ 8 D■ 7 R
8 Democrats
7 Republicans